Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Adrenal Function in Critical Illness
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), July 2008
Sponsored by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00156767
  Purpose

An appropriate hypothalamic-pituitary-adrenal (HPA) axis response is required to survive critical illness. Primary adrenal insufficiency, relative adrenal insufficiency, tissue resistance to glucocorticoids, ACTH deficiency and immune-mediated inhibition of the HPA axis may impair the secretion or action of glucocorticoids in critically ill patients. Adrenal insufficiency is estimated to occur in up to 77% of critically ill patients, but currently, there is no consensus on the diagnostic criteria for adrenal insufficiency in this setting, and standard testing does not discriminate among the aforementioned factors. We will study the incidence and natural history of adrenal insufficiency in critically ill patients to further define adrenal insufficiency and provide data to develop diagnostic tests. Clinical features and outcomes will be correlated with laboratory measurements of hormones, cytokines and glucocorticoid action. Healthy volunteers will undergo cortrosyn tests with measurement of free cortisol levels to develop a normative range for this endpoint.

Previous glucocorticoid use, if prolonged and supraphysiologic, also inhibits the HPA and can result in adrenal insufficiency. Patients with short intermittent courses of glucocorticoid administration have not been studied well, and may also be at risk. To gain further information about this group, patients receiving pulse glucocorticoid doses as part of bone marrow transplant regimens at the Clinical Center will also be studied.


Condition
Adrenal Insufficiency

Genetics Home Reference related topics: X-linked adrenoleukodystrophy
MedlinePlus related topics: Critical Care
Drug Information available for: Hydrocortisone Cortisol 21-phosphate Cortisol succinate Hydrocortamate Hydrocortisone 21-sodium succinate Hydrocortisone acetate Hydrocortisone cypionate Hydrocortisone hemisuccinate Proctofoam-HC Cosyntropin Epinephrine Epinephrine bitartrate
U.S. FDA Resources
Study Type: Observational
Official Title: Adrenal Function in Critical Illness

Further study details as provided by National Institutes of Health Clinical Center (CC):

Study Start Date: October 2004
Detailed Description:

An appropriate hypothalamic-pituitary-adrenal (HPA) axis response is required to survive critical illness. Primary adrenal insufficiency, relative adrenal insufficiency, tissue resistance to glucocorticoids, ACTH deficiency and immune-mediated inhibition of the HPA axis may impair the secretion or action of glucocorticoids in critically ill patients. Adrenal insufficiency is estimated to occur in up to 77 percent of critically ill patients, but currently, there is no consensus on the diagnostic criteria for adrenal insufficiency in this setting, and standard testing does not discriminate among the aforementioned factors. We will study the incidence and natural history of adrenal insufficiency in critically ill patients to further define adrenal insufficiency and provide data to develop diagnostic tests. Clinical features and outcomes will be correlated with laboratory measurements of hormones, cytokines and glucocorticoid action. Healthy volunteers will undergo cortrosyn tests with measurement of free cortisol levels to develop a normative range for this endpoint. Patients with known adrenal insufficiency will also be studied to help determine the clinical utility of diagnostic tests among these different groups.

Previous glucocorticoid use, if prolonged and supraphysiologic, also inhibits the HPA axis and can result in adrenal insufficiency. Patients with short intermittent courses of glucocorticoid administration have not been studied well, and may also be at risk. To gain further information about this group, patients receiving pulse glucocorticoid doses as part of bone marrow transplant regimens at the Clinical Center will also be studied.

  Eligibility

Ages Eligible for Study:   15 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • EXCLUSION CRITERIA - ALL ARMS OF STUDY

Women of reproductive age will also undergo a pregnancy test (urine hCG) prior to starting the testing procedure. If the woman is determined to be pregnant, she will not be able to participate in this study.

INCLUSION CRITERIA - CRITICAL CARE COMPONENT:

Diagnosis of sepsis by the primary clinical provider in the ICU.

Diagnosis of the above is based on diagnostic criteria for sepsis as defined by the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference as listed below:

Infection, documented or suspected, and some of the following:

General variables

  • Fever (core temperature greater than 38.3 C)
  • Hypothermia (core temperature greater than 36C)
  • Heart Rate greater than 90 min or greater than 2 SD above the normal value for age
  • Tachypnea
  • Altered mental status
  • Significant edema or positive fluid balance (greater than 20ml/kg over 24 hours)
  • Hyperglycemia (plasma glucose greater than 120 mg/dl) in the absence of diabetes

Inflammatory variables

  • Leukocytosis (WBC count greater than 12,000 uL)
  • Leukopenia (WBC count less than 4000 uL)
  • Normal WBC count with greater than 10 percent immature forms
  • Plasma C-reactive protein greater than 2 SD above the normal value
  • Plasma procalcitonin greater than 2 SD above the normal value

Hemodynamic variables

  • Arterial hypotension (SBP less than 90mm Hg, MAP less than 70, or an SBP decrease greater than 40 mm Hg in adults or less than 2 SD below normal for age)
  • SvO2 greater than 70 percent
  • Cardiac Index greater than 3.5L min(-1) M(-23)

EXCLUSION CRITERIA - CRITICAL CARE COMPONENT:

Pregnancy

Age less than 15 years at the Clinical Center; age less than 18 years at Georgetown or Suburban Hospitals

On glucocorticoids or megace within two weeks of admission unless using more than one of the following medications, patients taking inhaled corticosteriods (less than 1.5 mg/day budesonide, beclomethasone dipropionate and triamcinolone acetonide and less thab 0.75 mg/day for fluticasone propionate) or intranasal corticosteriods will not be excluded.

Patients who have received chronic steroid suppressive medications, i.e. etomidate, ketoconazole (Patients receiving etomidate for intubation purposes as a one time dose will not be excluded)

End stage renal or liver disease (creatinine clearance estimated as less than 20 cc/min by the cockcroft-gault equation: (140 - age) times lean body weight (kg)/ pCr (mg/dl) times 72, in patients with stable renal function; patients requiring dialysis; acute or fulminant hepatitis, alcoholic hepatitis, chronic severe hepatitis, severe obstructive hepatitis, severe coagulopathy, extrahepatic manifestations of ESLD, i.e. hypoxia, cardiomyopathy, acute renal failure)

Known or anticipated blood withdrawal within 6 weeks that exceeds the NIH guidelines of 450 l/six weeks in adults or 7 ml/kg/six weeks in children.

INCLUSION CRITERIA - BONE MARROW TRANSPLANT COMPONENT:

Participation in a Clinical Center bone marrow transplant protocol for breast cancer (generally Allogeneic Breast Protocol 2: Phase 1 Trial of T cell Exchange with Th2/Tc2 Cells for Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for Metastatic Breast Cancer), or for hematologic malignancy (generally either: T-cell depleted, reduced intensity allogeneic stem cell transplant from haploidentical related donors for hematologic malignancies: A sequential dose escalation study of donor Th2/Tc2 cells or Th2, Sirolimus in Allogeneic HSCT.

Agreement from the oncologist PI that the patient may participate in this protocol.

EXCLUSION CRITERIA - BONE MARROW TRANSPLANT COMPONENT:

The presence of any contraindication to insulin tolerance testing-e.g.cardiovascular or cerebrovascular disease or any seizure history.

Pregnancy

Age less than 15 years

End stage renal or liver disease as defined under the critical care section

Known or anticipated blood withdrawal within 6 weeks that exceeds the NIH guidelines of 450 ml/six weeks in adults.

INCLUSION CRITERIA - HEALTHY VOLUNTEER COMPONENT:

Adults aged at least 18 years will be recruited.

EXCLUSION CRITERIA - HEALTHY VOLUNTEER COMPONENT:

Severe hepatic, renal, cardiac, psychiatric or neurological illnesses

More than two weeks of oral antifungal or glucocorticoid medications or near daily use of topical glucocorticoids with broken skin. Frequent use of topical antifungal agents will be considered on a case-by-case basis.

Pregnancy

INCLUSION CRITERIA - KNOWN ADRENAL INSUFICIENTY COMPONENT:

Documented longstanding primary or secondary adrenal insufficiency

EXCLUSION CRITERIA - KNOWN ADRENAL INSUFFICNCY COMPONENT:

Pregnancy

INCLUSION CRITERIA - TRANSIENT ADRENAL INSUFICIENTY COMPONENT:

Recent uncomplicated successful transsphemoidal surgery for Cushing's disease with serum cortisol level less than 5 micro g/dl

EXCLUSION CRITERIA - TRANSIENT ADRENAL INSUFFICNCY COMPONENT:

Supra physiologic dosing of glucocorticoids as a treatment for another underlying medical disorder or surgical complication

Pregnancy

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00156767

Contacts
Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Suburban Hospital Recruiting
Bethesda, Maryland, United States, 20814
Sponsors and Collaborators
  More Information

NIH Clinical Center Detailed Web Page  This link exits the ClinicalTrials.gov site

Publications:
Study ID Numbers: 050013, 05-CH-0013
Study First Received: September 9, 2005
Last Updated: December 10, 2008
ClinicalTrials.gov Identifier: NCT00156767  
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Critical Care
Adrenal Insufficiency
Septic Shock
Cortrosyn
Steroids
Cortisol
Critical Care Unit
Adrenal Insufficiency
Adrenal Gland Function
Healthy Volunteer
HV

Study placed in the following topic categories:
Adrenal Insufficiency
Addison's disease
Hydrocortisone
Autoimmune Diseases
Cortisol succinate
Adrenal Gland Diseases
Endocrine System Diseases
Cosyntropin
Healthy
Hypoadrenalism
Adrenal gland hypofunction
Shock
Critical Illness
Adrenoleukodystrophy
Shock, Septic
Addison Disease
Hydrocortisone acetate
Endocrinopathy
Epinephrine
X-linked adrenoleukodystrophy

Additional relevant MeSH terms:
Disease Attributes
Pathologic Processes
Immune System Diseases

ClinicalTrials.gov processed this record on January 15, 2009